NCT02346760View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Herpes Simplex Virus Infection

Interventions

DRUG

UB-621

100 mg/ml, subcutaneous injection

Trial Locations (1)

11217

Taipei Veterans General Hospital, Taipei

Sponsors

Lead Sponsor

United BioPharma

All Listed Sponsors

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

lead

United BioPharma

INDUSTRY